- Home
- CMPX vs ELDN Comparison
CMPX vs ELDN Comparison
Compare CMPX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- ELDN
- Stock Information
- Founded
- CMPX 2014
- ELDN 2004
- Country
- CMPX United States
- ELDN United States
- Employees
- CMPX N/A
- ELDN 31
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- ELDN Health Care
- Exchange
- CMPX Nasdaq
- ELDN Nasdaq
- Market Cap
- CMPX 229.5M
- ELDN 176.1M
- IPO Year
- CMPX N/A
- ELDN N/A
- Fundamental
- Price
- CMPX $1.75
- ELDN $2.99
- Analyst Decision
- CMPX Strong Buy
- ELDN Strong Buy
- Analyst Count
- CMPX 8
- ELDN 1
- Target Price
- CMPX $13.38
- ELDN $16.00
- AVG Volume (30 Days)
- CMPX 2.8M
- ELDN 249.0K
- Earning Date
- CMPX 05-12-2025
- ELDN 05-08-2025
- Dividend Yield
- CMPX N/A
- ELDN N/A
- EPS Growth
- CMPX N/A
- ELDN N/A
- EPS
- CMPX N/A
- ELDN N/A
- Revenue
- CMPX $850,000.00
- ELDN N/A
- Revenue This Year
- CMPX $47.65
- ELDN N/A
- Revenue Next Year
- CMPX $2,767.57
- ELDN N/A
- P/E Ratio
- CMPX N/A
- ELDN N/A
- Revenue Growth
- CMPX N/A
- ELDN N/A
- 52 Week Low
- CMPX $0.77
- ELDN $1.55
- 52 Week High
- CMPX $4.08
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- CMPX 41.42
- ELDN 39.03
- Support Level
- CMPX $1.60
- ELDN $2.63
- Resistance Level
- CMPX $1.78
- ELDN $3.21
- Average True Range (ATR)
- CMPX 0.27
- ELDN 0.24
- MACD
- CMPX 0.03
- ELDN 0.03
- Stochastic Oscillator
- CMPX 38.01
- ELDN 45.24
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.